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The objective of this study was to develop Euro-
pean League Against Rheumatism/American College of
Rheumatology classification criteria for polymyalgia
rheumatica (PMR). Candidate criteria were evaluated
in a 6-month prospective cohort study of 125 patients
with new-onset PMR and 169 non-PMR comparison
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subjects with conditions mimicking PMR. A scoring
algorithm was developed based on morning stiffness
>45 minutes (2 points), hip pain/limited range of
motion (1 point), absence of rheumatoid factor and/or
anti–citrullinated protein antibody (2 points), and ab-
sence of peripheral joint pain (1 point). A score >4 had
68% sensitivity and 78% specificity for discriminating
all comparison subjects from PMR. The specificity was
higher (88%) for discriminating shoulder conditions
from PMR and lower (65%) for discriminating RA from
PMR. Adding ultrasound, a score >5 had increased
sensitivity to 66% and specificity to 81%. According to
these provisional classification criteria, patients >50
years old presenting with bilateral shoulder pain, not
better explained by an alternative pathology, can be
classified as having PMR in the presence of morning
stiffness >45 minutes, elevated C-reactive protein
and/or erythrocyte sedimentation rate, and new hip
pain. These criteria are not meant for diagnostic pur-
poses.
Polymyalgia rheumatica (PMR) is a common
inflammatory rheumatic disease of older individuals and
a common indication for long-term corticosteroid ther-
apy (1–3). PMR is also subject to wide variations of
clinical practice, due to the considerable uncertainty
related to diagnosis, course, and management in primary
and secondary care (4–7). There is no diagnostic labo-
ratory test, inflammatory markers are not specific, and
clinicians often turn to the corticosteroid response as a
“test of treatment” to establish the diagnosis (1,2,8).
Difficulties in diagnosing and classifying patients
with PMR are inherent in its definitions (9,10). The
proximal pain and stiffness syndrome can occur at
presentation in many other rheumatologic inflammatory
illnesses in older people (1,2,7,9). Approximately half of
patients diagnosed with PMR may have distal manifes-
tations such as peripheral arthritis, hand swelling with
pitting edema, and carpal tunnel syndrome (1,2,7,11).
Polymyalgic presentation is common in late-onset rheu-
matoid arthritis (RA) and spondylarthritis and is also
associated with giant cell arteritis in 10–30% of cases
(1,2). Heterogeneity in the disease course, uncertainty
regarding disease assessment parameters, and evolution
of alternative diagnoses on followup complicate the
management of PMR (9,12–15). For the above reasons a
safe and specific approach preferring a relative under-
diagnosis to an overdiagnosis is needed in PMR (9,11).
Uniform responsiveness to low doses of cortico-
steroids has been assumed to be a cardinal feature of
PMR. However, there is little hard evidence to substan-
tiate this assertion. A previous report showed that 3
weeks after starting prednisolone 15 mg a day only 55%
showed a complete response to therapy (10). This also
emphasizes that clinical trials of novel effective agents
are needed in PMR.
The lack of standardized classification criteria
has been a major factor hampering the development of
rational therapeutic approaches (12,16,17) and causing
difficulties in evaluating patients in clinical studies. In
response to a European League Against Rheumatism
(EULAR)/American College of Rheumatology (ACR)
initiative, a criteria development work group convened
in 2005.
A systematic literature review, a 3-phase hybrid
consensus process, and a wider survey were undertaken
to identify candidate criteria items (18). The first stage
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consisted of a meeting of 27 international experts who
anonymously rated 68 potential criteria identified
through literature review. In the second round the
experts were provided with the results of the first round
and re-rated the criteria items. In the third round the
wider acceptance of the chosen criteria (50% support)
was evaluated using a survey of 111 rheumatologists and
53 nonrheumatologists in North America and western
Europe.
In round 3, over 70% of respondents agreed on
the importance of 7 core criteria (all achieving 100%
support in round 2). These were aged 50 years or older,
symptom duration 2 weeks or longer, bilateral shoulder
and/or pelvic girdle aching, duration of morning stiffness
more than 45 minutes, elevated erythrocyte sedimenta-
tion rate (ESR), elevated C-reactive protein (CRP), and
rapid corticosteroid response. More than 70% agreed on
assessing pain and limitation of shoulder (84%) and/or
hip (76%) motion, but agreement was low for peripheral
signs (e.g., carpal tunnel syndrome, tenosynovitis, peri-
pheral arthritis).
The group reached consensus on the need for a
prospective cohort study to evaluate the disease course
from presentation in patients included on the basis of
proximal pain and stiffness, with evaluations over a
6-month period while receiving a standardized cortico-
steroid treatment regimen (7,18–25). The group also
agreed to assess musculoskeletal ultrasound as part of
the PMR classification criteria. In this paper, we present
the results from this prospective study and propose new
classification criteria for PMR.
STUDY DESIGN AND METHODS
Consensus decisions about study design. A priori, the
work group decided that a specific approach should be ad-
opted for classifying newly presenting patients with bilateral
shoulder pain as PMR (18). The group agreed on the follow-
ing:
1. Patients presenting with polymyalgic syndrome
should have stepwise evaluation on the basis of inclusion and
exclusion criteria, response to a standardized corticosteroid
challenge, and followup confirmation. The criteria items would
be agreed-upon clinical features and laboratory investigations.
2. The need to standardize response to corticosteroid
therapy in PMR. Because the goal of classification criteria is to
identify patients for enrollment into clinical trials before any
treatment, the response to corticosteroid therapy should be
used in verifying the classification of a patient as having PMR,
although it should not be used as a classification criterion.
Because scientific evidence is poor as to what constitutes such
a response it was agreed (75% agreement) this response
would be defined as 75% global response in clinical and
laboratory parameters within 7 days of corticosteroid challenge
with 15 mg oral prednisone or prednisolone and subsequent
resolution of inflammatory indices (18).
3. That a prospective study would be needed to evalu-
ate the disease course from presentation in patients included
on the basis of the mandatory “core” criteria of proximal pain
and stiffness. New-onset bilateral shoulder pain was selected as
the main eligibility criterion as the percentage of PMR pre-
senting with hip pain without shoulder pain was very small
(5%), and that as hip girdle pain is due to a wide range of
conditions, it would require the enrollment of an impracticably
large number of comparator patient groups (18). The study
would evaluate at prespecified intervals symptoms, examina-
tion, investigations, and their evolution with standardized
corticosteroid treatment in a prospective cohort of patients
with new-onset bilateral shoulder pain (comparing the PMR
case cohort with the comparator cohort of mimicking condi-
tions) over a 6-month period.
4. Musculoskeletal ultrasound should be evaluated in a
substudy as a feasible mode of investigation of possible PMR.
A secondary objective of this substudy would be the evaluation
of clinical and patient-based outcomes in PMR over a 6-month
period (26,27).
Study population. The study was a prospective cohort
study that included a cohort of patients with new-onset PMR
and a comparison cohort of non-PMR patients with various
conditions mimicking PMR. Study subjects were recruited
from 21 community-based and academic rheumatology clinics
in 10 European countries and the USA. Inclusion criteria for
PMR patients were age 50 years or older, new-onset bilateral
shoulder pain, and no corticosteroid treatment (for any con-
dition) within 12 weeks before study entry, fulfilling all the
inclusion and exclusion criteria defined in our previous report
and in accordance with the judgment of the participating
investigator that the patient had PMR (18). Every effort was
made to choose patients across the spectrum of disease
severity. Corticosteroid treatment for PMR patients was initi-
ated according to a predefined treatment protocol starting with
15 mg a day oral prednisone for weeks 1 and 2, 12.5 mg a day
for weeks 3 and 4, 10 mg a day for weeks 6–11, 10 mg/7.5 mg
every other day for weeks 12–15, 7.5 mg a day for weeks 16–25,
and tapering according to treatment response from week 26
onward. The gold standard for the pre-steroid diagnosis of
PMR was established as above at presentation and when the
diagnosis was maintained without an alternative diagnosis at
week 26 of followup.
The non-PMR comparison cohort included conditions
representative of the types that need to be distinguished from
PMR, in both primary and secondary care. Inclusion criteria
for the non-PMR comparison cohort were age 50 years or
older, new-onset bilateral shoulder pain, and a diagnosis of
either inflammatory or noninflammatory conditions, including
new-onset RA, connective tissue diseases, various shoulder
conditions (e.g., bilateral rotator cuff syndrome and/or adhe-
sive capsulitis, rotator cuff tear, glenohumeral osteoarthritis),
fibromyalgia, generalized osteoarthritis, and others. Patients
known to have the condition for12 weeks before the baseline
evaluation (except fibromyalgia and chronic pain) were not
eligible for inclusion. PMR patients with clinical suspicion of
giant cell arteritis were included as part of the comparison
cohort because these patients required different corticosteroid
doses. Patients in the comparison cohort were included on the
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basis of clinician diagnosis and not on formal criteria. No
guidelines were provided for treatment of the conditions in the
comparison cohort.
Ethics board approval was obtained at all participating
institutions before initiation of the study, and all participants
gave written informed consent before enrollment.
Followup and data collection. PMR patients were
evaluated at baseline, and at 1, 4, 12, and 26 weeks. At each
followup visit, clinical evaluation included response to cortico-
steroid therapy and opinion on the emergence of alternative
diagnoses. Patients not considered as having PMR at any time
were evaluated and treated according to accepted clinical
practice. They were excluded from the PMR cohort and
included in the non-PMR comparison cohort. Patients in the
comparison cohort were evaluated at baseline and at 26 weeks.
Data were collected using standardized data collection
forms and questionnaires translated into national languages.
Data collection included the candidate inclusion/exclusion
criteria items for classification of PMR, physical examination,
and assessment of corticosteroid response. Criteria items were
age 50 years or older, symptom duration 2 weeks or more,
bilateral shoulder and/or pelvic girdle aching, recent weight
loss 2 kg, duration of morning stiffness 45 minutes, ele-
vated ESR, elevated CRP, and rapid response of symptoms to
corticosteroids (75% global response within 1 week to
prednisolone/prednisone 15–20 mg a day). Pain was assessed
using a horizontal 100-mm visual analog scale (VAS) in 4
separate locations (shoulder, pelvic, neck, and overall) with 0
indicating no pain and 100 indicating worst pain. Morning
stiffness (in the past 24 hours) was assessed in minutes;
functional status and quality of life were assessed by the
modified Health Assessment Questionnaire (M-HAQ) and
Short Form 36. A 100-mm VAS was also used for recording
global well-being measures (patient and physician global) and
fatigue. Physical examination included the presence or absence
of tenderness, pain on movement, and limitation of the
shoulders and hips. Aspects of corticosteroid therapy including
dose, therapeutic response, and change in dose and therapy
discontinuation were documented.
Data regarding laboratory measures (including ESR,
CRP, rheumatoid factor [RF], and anti–citrullinated protein
antibody [ACPA]) were obtained from clinically ordered tests
performed at each study center. As the laboratory assays used
at each center varied, test results were classified as normal/
abnormal using the reference ranges from each center (see
Supplementary Table 1, available on the Arthritis & Rheuma-
tism web site at http://onlinelibrary.wiley.com/journal/10.1002/
(ISSN)1529-0131). Both PMR and non-PMR subjects under-
went ultrasound evaluation of shoulders and hips at baseline
and at 26 weeks. Evaluations were made according to EULAR
guidelines (28) to assess for features previously reported to be
associated with PMR, including bicipital tenosynovitis, sub-
acromial and subdeltoid bursitis, trochanteric bursitis, and
glenohumeral and hip effusion. A rheumatologist or radiolo-
gist experienced in musculoskeletal ultrasound performed the
ultrasound examination using linear probes with the frequency
range 6–10 MHz for shoulders and linear or curved array
probes with the frequency range 5–8 MHz for hips.
Statistical analysis. Descriptive statistics (means, per-
centages, etc.) were used to summarize the candidate criteria
data. Demographics (age and gender) and candidate criteria
were compared between PMR and comparison subjects using
chi-square and rank sum tests. Several statistical approaches
were considered in order to develop a scoring algorithm for
PMR and to assess the proposed classification criteria in
patients judged by expert clinician investigators to have PMR
26 weeks after enrollment (29).
First, logistic regression models to distinguish PMR
patients from all comparison subjects and each subset of
comparison subjects were examined. The C statistic, a measure
of concordance analogous to the area under the receiver
operating characteristic curve, was used to assess the ability of
each individual criterion to distinguish between PMR and
comparison subjects. The C statistic ranges from 0.5 to 1, with
0.5 indicating a criterion that provides no information. The
sensitivity, specificity, and the positive and negative likelihood
ratios were also examined.
Second, exploratory factor analysis was used to exam-
ine the interdependencies between the candidate criteria (30).
Maximum-likelihood factor analysis with varimax rotation was
used. Maximum-likelihood tests were used to examine good-
ness of fit (e.g., to determine the number of factors). This
method is thought to be superior to the eigenvalue 1 or
Cattell’s scree plot method for selecting the number of factors
(30). For each factor, variables with factor loadings 0.5 were
examined and found to represent a similar domain. This
technique allowed a reduction of the number of variables, as
one variable from each factor was examined in multivariable
logistic regression models. In addition, to avoid discarding a
relevant domain as identified by expert consensus, a few of the
variables with factor loading between 0.4 and 0.5 were also
considered in the multivariable models.
Classification trees including the variables determined
by the factor analysis were also considered, but were not found
to be optimal for distinguishing PMR from comparison sub-
jects (31,32). An integer scoring algorithm was defined based
on the odds ratios in the final multivariable logistic regression
model. Performance characteristics (sensitivity, specificity,
etc.) of this scoring algorithm were assessed. In addition, the
utility of ultrasound assessments for classifying PMR patients
was examined using factor analysis and adding potential ultra-
sound criteria to the scoring algorithm. Odds ratios for clinical
criteria varied somewhat in the scoring algorithm that included
ultrasound criteria. Scoring weights based on both models
were considered and found to perform similarly, so a common
set of scoring weights was used for the clinical items in both
algorithms in order to ease comparison and application of the
criteria.
Finally, gradient boosting regression tree models,
which are a machine learning technique, were examined to
determine whether a better prediction could be achieved using
a more complex algorithm (33).
RESULTS
At baseline, 128 patients were recruited into the
PMR cohort and 184 patients were recruited into the
non-PMR comparison cohort. During followup, 10 PMR
patients were reclassified as not having PMR and moved
into the non-PMR cohort. Similarly, 8 non-PMR com-
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parison cohort patients were reclassified as having PMR
and moved into the PMR cohort. In addition, 7 patients
(1 PMR and 6 non-PMR) were excluded due to missing
information, and 2 non-PMR subjects with age 50
years and 9 non-PMR subjects with no shoulder pain
were also excluded. Therefore, the final analysis was
based on 125 PMR and 169 non-PMR subjects.
The diagnoses of the 169 non-PMR subjects (see
Supplementary Table 2, available on the Arthritis &
Rheumatism web site at http://onlinelibrary.wiley.com/
journal/10.1002/(ISSN)1529-0131) were new-onset RA
(49 [29%]), new-onset other seronegative arthritis (20
[12%]), new-onset connective tissue diseases or vasculi-
tis (9 [5%]), shoulder conditions (52 [31%]), chronic
pain (26 [15%]), infection (5 [3%]), previously undiag-
nosed malignancy (4 [2%]), and 2 each of endocrinopa-
thy and neurologic disorders.
The distribution of the candidate classification
criteria for the 125 PMR patients and 169 non-PMR
comparison subjects (all, RA only, and shoulder condi-
tion only) is displayed in Table 1. Criteria items present
in 80% of the PMR subjects were 2 weeks duration
of symptoms, bilateral shoulder pain, and elevated CRP
and/or ESR. Relevant clinical features that best discrim-
inated RA from PMR were peripheral synovitis, the
presence of RF and/or ACPA, and hip pain/limited
range of motion. Features best discriminating shoulder
conditions from PMR were hip pain/limited range of
motion, morning stiffness, and elevated CRP and/or
ESR.
Development of a scoring algorithm. Table 2
shows the results of univariate logistic regression models
to distinguish PMR from all comparison subjects, RA
only, and shoulder conditions only. Criteria items re-
lated to hip involvement (pain, tenderness, limited
movement) had significant ability to discriminate PMR
from all comparison subjects, RA, and shoulder condi-
tions based on the C statistic. Early morning stiffness,
M-HAQ, weight loss, and raised laboratory markers of
inflammation distinguished PMR from comparison sub-
jects, particularly those with shoulder conditions. The
presence of ACPA and/or RF, peripheral synovitis, and
joint pains had significant ability (with high C statistic)
to distinguish PMR from RA. In addition, the odds
Table 1. Distribution of candidate criteria for 125 PMR patients and 169 comparison subjects*
PMR
(n  125)
Comparison
subjects
(n  169) P
RA
(n  49) P
Shoulder
conditions
(n  52)† P
Age, mean  SD years 71.5 8.4 67.0  9.6 0.001 68.6 10.0 0.06 67.0 10.6 0.017
Female sex 72 (58) 112 (66) 0.13 28 (57) 0.96 35 (67) 0.23
Duration of symptoms 2 weeks 121 (97) 163 (96) 0.87 47 (96) 0.77 51 (98) 0.64
Duration of symptoms, mean  SD weeks 10.0  7.2 14.4  19.1 0.17 13.8 16.1 0.62 12.9 11.8 0.21
Bilateral shoulder aching 124 (99) 162 (96) 0.08 46 (94) 0.035 50 (96) 0.15
Bilateral pelvic girdle (hip) aching 91 (73) 90 (53) 0.001 28 (57) 0.046 21 (40) 0.001
Neck aching 71 (57) 92 (54) 0.69 29 (59) 0.78 27 (52) 0.55
Morning stiffness duration 45 minutes‡ 92 (77) 68 (43) 0.001 33 (69) 0.25 10 (20) 0.001
Morning stiffness duration, median (IQR)
minutes
120 (60, 240) 30 (5, 120) 0.001 60 (30, 180) 0.11 10 (0, 30) 0.001
Weight loss of 2 kg 45 (36) 40 (24) 0.021 16 (33) 0.68 4 (8) 0.001
Shoulder pain or limited range of motion 121 (97) 158 (93) 0.20 47 (96) 0.77 49 (94) 0.42
Hip pain or limited range of motion 71 (57) 59 (35) 0.001 15 (31) 0.002 12 (23) 0.001
Shoulder tenderness 96 (77) 126 (75) 0.66 40 (82) 0.49 34 (65) 0.12
Hip tenderness 59 (47) 47 (28) 0.001 12 (24) 0.006 9 (17) 0.001
Carpal tunnel syndrome 19 (15) 27 (16) 0.90 11 (22) 0.28 8 (15) 0.99
Peripheral synovitis (distal swelling, tenosynovitis,
or arthritis)‡
48 (39) 78 (46) 0.20 41 (84) 0.001 11 (21) 0.024
Other joint pain‡ 63 (51) 109 (66) 0.011 40 (85) 0.001 29 (57) 0.50
Abnormal CRP and/or ESR‡ 116 (96) 99 (63) 0.001 41 (85) 0.017 18 (41) 0.001
Presence of RF and/or ACPA‡ 11 (10) 37 (25) 0.004 19 (41) 0.001 5 (12) 0.79
Abnormal serum protein electrophoresis‡ 43 (52) 32 (35) 0.027 9 (36) 0.17 9 (35) 0.13
M-HAQ, mean  SD 1.2  0.6 0.8 0.6 0.001 1.1  0.7 0.32 0.5 0.6 0.001
* Values are number (percentage) unless specified. Percentages for laboratory results are the number of abnormal test results divided by the number
of patients tested. PMR  polymyalgia rheumatica; RA  rheumatoid arthritis; IQR  interquartile range; CRP  C-reactive protein; ESR 
erythrocyte sedimentation rate; RF  rheumatoid factor; ACPA  anti–citrullinated protein antibody; M-HAQ  modified Health Assessment
Questionnaire.
† Bilateral rotator cuff syndrome and/or adhesive capsulitis, rotator cuff tear, glenohumeral osteoarthritis.
‡ Data not available on all subjects.
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ratios for abnormal CRP and/or ESR were particularly
high. This resulted because only 5 PMR patients did not
have abnormal CRP and/or ESR, perhaps reflecting that
the diagnosis of PMR is less certain in the presence of
normal CRP and ESR. Therefore, abnormal CRP or
ESR would be included as a required criterion in the
scoring algorithm for PMR. Similarly, as all subjects in
the study were required to have shoulder pain, this was
also included as a required criterion for PMR.
Factor analysis revealed that 4 factors were suf-
ficient to represent all the criteria (see Supplementary
Table 3, available on the Arthritis & Rheumatism web site
at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)
1529-0131). These 4 factors were hip pain/tenderness,
peripheral synovitis or other joint pain, morning stiff-
ness, and shoulder tenderness. Note that duration of
symptoms, neck aching, carpal tunnel syndrome, weight
loss, presence of RF/ACPA, and M-HAQ did not play a
prominent role in any of the factors.
Next, multivariable logistic regression models
were used to determine the importance of each criterion
when assessed simultaneously (Table 3). Three models
Table 2. Univariate logistic regression models to distinguish subjects with PMR from comparison subjects*
PMR vs. all
comparison subjects PMR vs. RA
PMR vs. shoulder
conditions†
Variable
Odds ratio
(95% CI) C
Odds ratio
(95% CI) C
Odds ratio
(95% CI) C
Duration of symptoms 2 weeks 1.1 (0.3–4.0) 0.50 1.3 (0.2–7.3) 0.50 0.6 (0.1–5.4) 0.51
Shoulder pain or limited range of motion 2.1 (0.7–6.8) 0.52 1.3 (0.2–7.3) 0.50 1.9 (0.4–8.6) 0.51
Shoulder tenderness 1.1 (0.7–1.9) 0.51 0.7 (0.3–1.7) 0.52 1.8 (0.9–3.6) 0.56
Hip pain or limited range of motion 2.5 (1.5–3.9) 0.61 3.0 (1.5–6.0) 0.63 4.4 (2.1–9.1) 0.67
Hip tenderness 2.3 (1.4–3.8) 0.60 2.8 (1.3–5.8) 0.61 4.3 (1.9–9.5) 0.65
Neck aching 1.1 (0.7–1.8) 0.51 0.9 (0.5–1.8) 0.51 1.2 (0.6–2.3) 0.52
Morning stiffness duration 45 minutes 4.5 (2.6–7.7) 0.67 1.5 (0.7–3.3) 0.54 13.6 (6.0–31) 0.79
Weight loss 2 kg 1.8 (1.1–3.0) 0.56 1.2 (0.6–2.4) 0.52 6.8 (2.3–19.9) 0.64
Carpal tunnel syndrome 1.0 (0.5–1.8) 0.50 0.6 (0.3–1.5) 0.54 – –
Peripheral synovitis (distal swelling, tenosynovitis,
or arthritis)
0.7 (0.5–1.2) 0.54 0.1 (0.08–0.3) 0.72 2.4 (1.1–5.0) 0.59
Other joint pain 0.5 (0.3–0.9) 0.57 0.2 (0.1–0.4) 0.67 0.8 (0.4–1.5) 0.53
Abnormal CRP and/or ESR 13.8 (5.3–36) 0.67 4.0 (1.2–13) 0.55 33.5 (11–98) 0.78
Presence of RF and/or ACPA 0.4 (0.2–0.7) 0.57 0.2 (0.07–0.4) 0.66 0.9 (0.3–2.6) 0.51
Abnormal serum protein electrophoresis 2.0 (1.1–3.6) 0.58 1.9 (0.8–4.8) 0.58 2.0 (0.8–5.1) 0.59
M-HAQ (per 1-unit increase) 2.3 (1.6–3.4) 0.66 1.3 (0.7–2.2) 0.55 6.7 (3.2–14) 0.78
* PMR  polymyalgia rheumatica; 95% CI  95% confidence interval; RA  rheumatoid arthritis; CRP  C-reactive protein; ESR  erythrocyte
sedimentation rate; RF  rheumatoid factor; ACPA  anti–citrullinated protein antibody; M-HAQ  modified Health Assessment Questionnaire.
† Bilateral rotator cuff syndrome and/or adhesive capsulitis, rotator cuff tear, glenohumeral osteoarthritis.
Table 3. Multivariable logistic regression models*
Model based on factors
Model based on factors
without shoulder
tenderness plus presence
of RF/ACPA
Model based on factors
plus presence of
RF/ACPA and M-HAQ
Criterion
Odds ratio
(95% CI) P
Odds ratio
(95% CI) P
Odds ratio
(95% CI) P
Hip pain or limited range of motion 2.7 (1.5–4.8) 0.001 2.1 (1.1–4.0) 0.019 1.6 (0.8–3.2) 0.16
Other joint pain 0.4 (0.2–0.6) 0.001 0.4 (0.2–0.7) 0.002 0.3 (0.1–0.6) 0.001
Morning stiffness duration 45 minutes 5.2 (2.9–9.4) 0.001 6.2 (3.2–11.8) 0.001 4.8 (2.4–9.6) 0.001
Shoulder tenderness 0.9 (0.5–1.8) 0.80
Presence of RF or ACPA 0.3 (0.1–0.8) 0.009 0.3 (0.1–0.8) 0.013
M-HAQ, per 1-unit increase 2.4 (1.4–4.2) 0.002
Likelihood ratio test for additional terms P  0.001 P  0.001
C statistic 79% 81% 81%
* 95% CI  95% confidence interval; RF  rheumatoid factor; ACPA  anti–citrullinated protein antibody; M-HAQ  modified Health
Assessment Questionnaire.
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were considered: 1) including the 4 factors identified in
factor analysis; 2) removing shoulder tenderness and
adding presence of RF/ACPA; and 3) subsequently
adding M-HAQ. While the subsequent additions ap-
peared to be significant, they also negatively impacted
the hip pain criteria. The utility of the inclusion of
M-HAQ was questionable, as hip pain was easier to
assess than M-HAQ in a clinical setting. Therefore, the
second model, which included hip pain, other joint pain,
morning stiffness, and abnormal RF/ACPA, was deemed
the best multivariable model.
Additional analyses were performed using classi-
fication trees and assessing combinations of criteria.
Classification trees were examined using 3 sets of poten-
tial variables: 1) the 4 identified factors; 2) adding
presence of RF/ACPA; and 3) subsequently adding
M-HAQ. The resulting trees were deemed inadequate.
For example, the second tree, which was fit using the
same 5 variables that were included in our scoring
algorithm, had a sensitivity of 66% and specificity of
66%. This specificity was lower than the scoring algo-
rithm developed from the logistic models. In addition,
this tree only included morning stiffness and absence of
RF and/or ACPA, so it was inadequate because it
excluded other domains deemed necessary for content
validity. Content validity requires that the set of criteria
identified is comprehensive. This was the case in all 3
trees. Therefore, classification trees were deemed to
have poorer performance and content validity than the
logistic regression models.
A scoring algorithm was developed (Table 4)
based on the multivariable logistic regression model
presented in Table 3 and included morning stiffness for
45 minutes (2 points), hip pain/limited range of motion
(1 point), absence of RF and/or ACPA (2 points), and
the absence of peripheral joint pain (1 point). The score
was evaluated using all PMR subjects (including the 5
with normal CRP/ESR) and all comparison subjects.
This was done to account properly for the influence of
CRP/ESR on the performance of the scoring algorithm.
A score of 4 or greater had 68% sensitivity and 78%
specificity for discriminating all comparison subjects
from PMR. The specificity was higher (88%) for dis-
criminating shoulder conditions from PMR and lower
(65%) for discriminating RA from PMR. The C statistic
for the scoring algorithm was 81%. A total of 40 PMR
patients (32%) and 38 comparison subjects (22%) were
incorrectly classified. The positive predictive value was
69% and the negative predictive value was 77%. Supple-
mentary Table 4 (http://onlinelibrary.wiley.com/journal/
10.1002/(ISSN)1529-0131) shows the sensitivity and
specificity for all possible cut points of the scoring
algorithm.
Finally, gradient boosting regression tree models,
which are a model averaging technique, were examined
to determine whether a better prediction could be
Table 4. Scoring algorithm with and without optional ultrasound criteria—required criteria: age 50 years, bilateral shoulder aching, and
abnormal CRP and/or ESR*
Criteria
Clinical criteria
(without ultrasound)†
Criteria including
ultrasound‡
Odds ratio
(95% CI) Points
Odds ratio
(95% CI) Points
Morning stiffness duration 45 minutes 6.2 (3.2–11.8) 2 5.0 (2.8–9.1) 2
Hip pain or limited range of motion 2.1 (1.1–4.0) 1 1.4 (0.8–2.6) 1
Absence of RF or ACPA 3.0 (1.3–6.8) 2 5.2 (2.1–12.6) 2
Absence of other joint pain 2.7 (1.4–5.0) 1 2.2 (1.3–4.0) 1
Ultrasound criteria
At least 1 shoulder with subdeltoid bursitis and/or biceps
tenosynovitis and/or glenohumeral synovitis (either posterior or
axillary) and at least 1 hip with synovitis and/or trochanteric
bursitis
2.6 (1.3–5.3) 1§
Both shoulders with subdeltoid bursitis, biceps tenosynovitis, or
glenohumeral synovitis
2.1 (1.2–3.7) 1¶
* CRP  C-reactive protein; ESR  erythrocyte sedimentation rate; 95% CI  95% confidence interval; RF  rheumatoid factor; ACPA 
anti–citrullinated protein antibody.
† The optimal cut point is 4. A patient with a score of 4 or more is categorized as having polymyalgia rheumatica (PMR).
‡ The optimal cut point is 5. A patient with a score of 5 or more is categorized as having PMR.
§ P  0.008.
¶ P  0.009.
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achieved using a more complex algorithm. The resulting
C statistic from the gradient boosting model was 80%,
which was quite comparable to the results for our
scoring algorithm. This indicated that we will not be able
to make better predictions from these data with another
modeling approach.
Ultrasound findings. Ultrasound was performed
in 120 PMR subjects, 154 of the comparison subjects
(including 46 with RA and 47 with shoulder conditions),
and 21 additional controls (not included in our study
cohorts) who did not have shoulder conditions. Patients
with PMR were more likely to have abnormal ultra-
sound findings in the shoulder (particularly subdeltoid
bursitis and biceps tenosynovitis), and somewhat more
likely to have abnormal findings in the hips than com-
parison subjects as a group (Table 5). PMR could not be
distinguished from RA on the basis of ultrasound, but
could be distinguished from non-RA shoulder condi-
tions and subjects without shoulder conditions.
Assessing the utility of ultrasound in classifying
PMR. Factor analysis (see Supplementary Table 5,
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)
1529-0131) revealed several strong factors potentially
useful for classifying patients with PMR from the ultra-
sound data. The inclusion of ultrasound findings in the
scoring algorithm resulted in improving the C statistic to
82%. A score of 5 or greater had 66% sensitivity and
81% specificity for discriminating all comparison sub-
jects from PMR. The specificity was higher (89%) for
discriminating shoulder conditions from PMR and lower
(70%) for discriminating RA from PMR. A total of 41
PMR patients (34%) and 30 comparison subjects (19%)
were incorrectly classified. The positive predictive value
was 72% and the negative predictive value was 75%.
Therefore, ultrasound findings were useful in discrimi-
nating PMR from shoulder conditions, but less so in
discriminating PMR from RA. Table 4 also shows the
scoring algorithm including the ultrasound criteria. Sup-
plementary Table 4 (http://onlinelibrary.wiley.com/
journal/10.1002/(ISSN)1529-0131) shows the sensitivity
and specificity for all possible cut points of the scoring
algorithm.
Response to corticosteroids in PMR. Complete
corticosteroid response at 4 weeks was seen in 71% of
patients and the response was sustained in 78% of
responders at 26 weeks. As expected by the plan for
tapering of the corticosteroids, the median prednisone
dose decreased from 15 mg at baseline to 5 mg at 26
weeks. Response to treatment (percentage improvement
in global pain VAS at weeks 4 and 26) was highly
correlated with percentage improvement in other VAS
measures (correlation 0.5 and P  0.001 at weeks 4
and 26), but was not correlated with percentage change
in corticosteroid dose (P  0.20 at week 4 and P  0.47
at week 26). There was no association between the
points obtained on either scoring algorithm and the
response to corticosteroids at 4 weeks (Spearman corre-
lation coefficient 0.09, P 0.38 for the scoring algorithm
including ultrasound) and 26 weeks (data not shown),
indicating that corticosteroid response cannot be used as
part of PMR classification.
We also reevaluated our risk score model for the
scoring algorithm using only the PMR subjects who
responded to corticosteroids. When the final risk score
Table 5. Ultrasound findings in 120 patients with PMR, 154 comparison subjects (including 46 with RA and 47 with shoulder conditions), and 21
subjects without shoulder conditions*
PMR
(n  120)
Comparison
subjects
(n  154)
RA
(n  46)
Shoulder
conditions
(n  47)
Subjects without
shoulder conditions
(n  21)
At least 1 shoulder with subdeltoid bursitis, biceps
tenosynovitis, or glenohumeral synovitis
83 70† 78 62† 19†
Both shoulders with subdeltoid bursitis, biceps
tenosynovitis, or glenohumeral synovitis
59 43† 65 26† 0†
At least 1 shoulder with subdeltoid bursitis or
biceps tenosynovitis
82 63† 72 53† 19†
Both shoulders with subdeltoid bursitis or biceps
tenosynovitis
57 35† 52 21† 0†
At least 1 hip with synovitis or trochanteric bursitis 38 23‡ 30 18‡ 0†
Both hips with synovitis or trochanteric bursitis 19 8† 9 4‡ 0‡
At least 1 shoulder and 1 hip with findings as above 33 16† 17‡ 11† 0†
Both shoulders and both hips with findings as above 12 7 6 2‡ 0
* Values are percents. RA  rheumatoid arthritis.
† P  0.01 compared with polymyalgia rheumatica (PMR).
‡ P  0.05 compared with PMR.
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model was recomputed using only the subset of subjects
with PMR who responded to corticosteroids (and all of
the comparison subjects), the odds ratios for each of the
criteria remained essentially unchanged. In addition, the
specificity was identical and the sensitivity increased by
an insignificant amount (0.5%).
Blinded reevaluation of selected PMR patients
and non-PMR controls. The reevaluation exercise
showed that most candidate criteria items performed
well in discriminating PMR patients from controls.
However, a third of the sample of PMR patients/
comparison subjects was difficult to classify. The high C
statistic levels associated with the corticosteroid re-
sponse and posttreatment CRP and ESR suggested that
the uncertainty originated from the pivotal role of
corticosteroids in the investigator assessment, in decid-
ing whether a patient does or does not have PMR. It
raises questions such as whether PMR always responds
adequately to corticosteroids and whether polymyalgic
RF-positive disease without peripheral synovitis can
occur (seeSupplementaryAppendix [http://onlinelibrary.
wiley.com/journal/10.1002/(ISSN)1529-0131)] for de-
tails).
DISCUSSION
This is the first international multicenter pro-
spective study examining consensus-based candidate
classification criteria for PMR proposed by an interna-
tional work group. Findings indicate that patients 50
years of age or older presenting with new bilateral
shoulder pain (not better explained by an alternative
diagnosis) and elevated CRP and/or ESR can be classi-
fied as having PMR in the presence of morning stiffness
of 45 minutes and new hip involvement (pain, tender-
ness, limited movement). The absence of peripheral
synovitis or of positive RA serology increases the likeli-
hood of PMR. While recognizing that RF particularly
may be present in patients with PMR, the absence of RF
serology is useful in distinguishing PMR from RA in
older patients for classification purposes (18,34). Ultra-
sound findings of bilateral shoulder abnormalities (sub-
acromial bursitis/bicipital tenosynovitis/glenohumeral
effusion) or abnormalities in 1 shoulder and hip (hip
effusion, trochanteric bursitis) may significantly improve
the specificity of the clinical criteria. These criteria are
not meant for diagnostic purposes and have not been
tested as diagnostic criteria.
Newer concepts of PMR are revealed by this and
other recent studies—heterogeneity at presentation and
course, lack of uniform responsiveness to low-dose
steroids, and overlap with inflammatory arthritis. How-
ever, we feel that at present these classification criteria
provide a basic framework for developing clinical trials
of novel therapies in PMR.
How should the PMR classification criteria be
applied? The target population will be patients aged 50
years or older presenting with new-onset (12 weeks)
bilateral shoulder pain and abnormal acute-phase re-
sponse. The criteria may only be applied to those
patients in whom the symptoms are not better explained
by an alternative diagnosis. Mimicking conditions in-
clude the inflammatory and noninflammatory conditions
studied as comparators in this report.
Four clinical and laboratory criteria along with
optional ultrasound criteria (Tables 4 and 6) can be
applied to eligible patients to identify patients with PMR
suitable for low-dose corticosteroid therapy. The scoring
scale is 0–6 (without ultrasound) and 0–8 (with ultra-
sound). In the absence of competing diagnoses, a score
of 4 or greater (without ultrasound), or 5 or greater
(with ultrasound) is indicative of PMR. Patients with a
score of less than 4 (based on clinical plus laboratory
criteria) cannot be considered to have PMR. Ultrasound
improves the specificity of PMR diagnosis, and shows
particularly good performance in differentiating PMR
from noninflammatory conditions and thus is a recom-
mended investigation for PMR.
Table 6. PMR classification criteria scoring algorithm—required
criteria: age 50 years, bilateral shoulder aching, and abnormal CRP
and/or ESR*
Points
without
US (0–6)
Points with
US (0–8)†
Morning stiffness duration 45 minutes 2 2
Hip pain or limited range of motion 1 1
Absence of RF or ACPA 2 2
Absence of other joint involvement 1 1
At least 1 shoulder with subdeltoid
bursitis and/or biceps tenosynovitis
and/or glenohumeral synovitis (either
posterior or axillary) and at least 1
hip with synovitis and/or trochanteric
bursitis
NA 1
Both shoulders with subdeltoid bursitis,
biceps tenosynovitis, or glenohumeral
synovitis
NA 1
* A score of 4 or more is categorized as polymyalgia rheumatica
(PMR) in the algorithm without ultrasound (US) and a score of 5 or
more is categorized as PMR in the algorithm with US. CRP 
C-reactive protein; ESR  erythrocyte sedimentation rate; RF 
rheumatoid factor; ACPA  anti–citrullinated protein antibody;
NA  not applicable.
† Optional ultrasound criteria.
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Classification criteria for PMR should be useful
for identifying patients appropriate for enrollment into
clinical trials of novel medications for the treatment of
PMR, and studying long-term outcomes in more homo-
geneous patient cohorts. Our analyses indicate that even
typical PMR patients at presentation may vary in their
response to low-dose corticosteroid therapy, indicating
that corticosteroid response is not reliable as a classifi-
cation feature for PMR. This is similar to other rheu-
matic diseases such as RA, in which phenotypically
similar patients may exhibit different responses to
disease-modifying antirheumatic drugs.
Strengths and limitations. The strengths of the
study relate to harnessing international effort to address
a disease area subject to wide variation of practice, to
develop agreement on the definition of what may or may
not be treated as PMR and what needs further evalua-
tion.
Our study methodology satisfies the ACR guide-
lines for the development of classification criteria for
rheumatic diseases (35). The consensus-based candidate
criteria were generated by a multispecialty international
group whose views were supported by the results of a
wide trans-Atlantic survey. The work group suggested a
prospective study designed to separate PMR patients
from comparison subjects in patients included on a
single eligibility criterion (new bilateral shoulder pain in
subjects 50 years).
This ensured an inception cohort longitudinal
observational design wherein the PMR cohort could be
compared with the comparison cohort at similar chro-
nological time points of disease. All PMR patients were
evaluated before treatment with corticosteroids, were
treated with a standard corticosteroid schedule, and
assessed at predetermined time points. Our study is in
keeping with the EULAR/ACR goal of developing
rheumatic disease classification criteria as opposed to
diagnostic criteria. We focused on subjects with new-
onset/incident disease, and a 6-month longitudinal fol-
lowup allowed an accurate evaluation of the disease
course and diagnoses. Previous criteria for PMR were
developed using cross-sectional comparisons. Only 2 of
the previous criteria were developed through an evalu-
ative process (20,36). Neither had a definition of the
“gold standard” diagnosis other than the physician con-
sidered the patient to have “unequivocal” PMR.
Another strength of our proposed classification
criteria is the imaging component. Musculoskeletal ul-
trasound has promise due to widespread availability,
feasibility, and good research evidence (18). The PMR
work group standardized the examination of shoulders
and hips by ultrasound for the purposes of the current
study (37). Our findings indicate that ultrasound evalu-
ation of hips and shoulders adds significantly to the
evaluation of the polymyalgic syndrome. The lack of a
“gold standard” and the challenge of circularity were
addressed through a blinded multirater reevaluation
exercise in selected cases and comparison subjects (see
Supplementary Appendix [http://onlinelibrary.wiley.
com/journal/10.1002/(ISSN)1529-0131)]). Most of the
candidate criteria items performed well. The misclassi-
fication of several subjects reflects the difficulty in
discriminating PMR from other inflammatory condi-
tions such as RA. This uncertainty originates from the
pivotal role of (and circular reasoning related to using)
the corticosteroid response in deciding whether a patient
does or does not have PMR. Although the proposed
scoring algorithm has high specificity for identifying
PMR patients, it is nevertheless unable to predict the
subsequent corticosteroid response, suggesting hetero-
geneity of disease course and treatment response. This
has also been reported previously (10,38).
While we were able to scrutinize the basis for
PMR diagnosis, no formal criteria were required for
diagnosis of the comparison conditions. This is a limita-
tion of the study. However, the study was led in all
centers by experienced rheumatologists with major clin-
ical and research interest in PMR and related condi-
tions. We did not include hip pain without shoulder pain
as an eligibility criterion for reasons discussed in the
Methods section. Funding constraints limited the fol-
lowup duration to only 6 months. We were also limited
by lack of funding for the central measurement of
laboratory data. Values of ESR, CRP, RF, and ACPA
were based on local laboratory assays. Our study ap-
proach reflects a pragmatic view, which perhaps lends
wider applicability to the results of the study.
Our classification algorithm had a C statistic of
81%, which exceeds the threshold of 80% that is con-
ventionally considered to be useful in clinical decision-
making. However, we suggest that the criteria are re-
garded as provisional at this point, awaiting validation in
a separate cohort.
In conclusion, patients aged 50 years or older
presenting with bilateral shoulder pain and elevated
CRP and/or ESR can be classified as having PMR in the
presence of morning stiffness for more than 45 minutes,
and new hip pain in the absence of peripheral synovitis
or positive RA serology. Using ultrasound, a score of 5
or greater had 66% sensitivity and 81% specificity for
discriminating all comparison subjects from PMR. In
our view, this approach can now be used to test eligibility
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for trials with newer therapies in PMR. A number of
future research questions are highlighted, including: 1)
Should PMR be considered as a part of the spectrum of
late-onset inflammatory arthritis? 2) Can polymyalgic
disease without peripheral synovitis occur in RF-positive
disease? 3) Can we diagnose PMR in patients with
normal acute-phase response? 4) What is the role of the
early introduction of disease-modifying antirheumatic
drugs in PMR?
We have collected and stored blood samples
from both the case and the comparator groups in the
study. We hope to develop research proposals using
these biospecimens to test several candidate biomarkers
in PMR. These proposals will also examine the acute-
phase response: whether stratification of the response
and differential levels of acute-phase reactants and
cytokines may function as additional classification crite-
ria items.
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